JPWO2020069433A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020069433A5 JPWO2020069433A5 JP2021517437A JP2021517437A JPWO2020069433A5 JP WO2020069433 A5 JPWO2020069433 A5 JP WO2020069433A5 JP 2021517437 A JP2021517437 A JP 2021517437A JP 2021517437 A JP2021517437 A JP 2021517437A JP WO2020069433 A5 JPWO2020069433 A5 JP WO2020069433A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- composition
- binding construct
- human
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 claims 42
- 239000000203 mixture Substances 0.000 claims 31
- 206010028980 Neoplasm Diseases 0.000 claims 27
- 239000000427 antigen Substances 0.000 claims 26
- 102000036639 antigens Human genes 0.000 claims 26
- 108091007433 antigens Proteins 0.000 claims 26
- 238000000034 method Methods 0.000 claims 13
- 238000002560 therapeutic procedure Methods 0.000 claims 10
- 230000008595 infiltration Effects 0.000 claims 9
- 238000001764 infiltration Methods 0.000 claims 9
- 210000004027 cell Anatomy 0.000 claims 8
- 230000005855 radiation Effects 0.000 claims 8
- 238000001514 detection method Methods 0.000 claims 7
- 238000012544 monitoring process Methods 0.000 claims 7
- 238000009472 formulation Methods 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 5
- 229940124597 therapeutic agent Drugs 0.000 claims 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 239000000700 radioactive tracer Substances 0.000 claims 4
- 206010025323 Lymphomas Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 208000035269 cancer or benign tumor Diseases 0.000 claims 3
- 238000001727 in vivo Methods 0.000 claims 3
- 239000003550 marker Substances 0.000 claims 3
- GNMUEVRJHCWKTO-FQEVSTJZSA-N 6h-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-6-acetamide, 4-(4-chlorophenyl)-n-(4-hydroxyphenyl)-2,3,9-trimethyl-, (6s)- Chemical compound C([C@@H]1N=C(C2=C(N3C(C)=NN=C31)SC(=C2C)C)C=1C=CC(Cl)=CC=1)C(=O)NC1=CC=C(O)C=C1 GNMUEVRJHCWKTO-FQEVSTJZSA-N 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 206010061818 Disease progression Diseases 0.000 claims 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 2
- 229950000080 birabresib Drugs 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 230000003247 decreasing effect Effects 0.000 claims 2
- 238000003745 diagnosis Methods 0.000 claims 2
- 230000005750 disease progression Effects 0.000 claims 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 2
- 238000003384 imaging method Methods 0.000 claims 2
- 230000009545 invasion Effects 0.000 claims 2
- 201000007270 liver cancer Diseases 0.000 claims 2
- 208000014018 liver neoplasm Diseases 0.000 claims 2
- 229960002621 pembrolizumab Drugs 0.000 claims 2
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 2
- 238000001356 surgical procedure Methods 0.000 claims 2
- 210000001519 tissue Anatomy 0.000 claims 2
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 claims 2
- UWNXGZKSIKQKAH-SSEXGKCCSA-N (2R)-2-[[2-[(3-cyanophenyl)methoxy]-4-[[3-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-methylphenyl]methoxy]-5-methylphenyl]methylamino]-3-hydroxypropanoic acid Chemical compound Cc1cc(CN[C@H](CO)C(O)=O)c(OCc2cccc(c2)C#N)cc1OCc1cccc(c1C)-c1ccc2OCCOc2c1 UWNXGZKSIKQKAH-SSEXGKCCSA-N 0.000 claims 1
- YPBKTZBXSBLTDK-PKNBQFBNSA-N (3e)-3-[(3-bromo-4-fluoroanilino)-nitrosomethylidene]-4-[2-(sulfamoylamino)ethylamino]-1,2,5-oxadiazole Chemical compound NS(=O)(=O)NCCNC1=NON\C1=C(N=O)/NC1=CC=C(F)C(Br)=C1 YPBKTZBXSBLTDK-PKNBQFBNSA-N 0.000 claims 1
- RJNGJYWAIUJHOJ-DSHIFKSRSA-N (3r,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-amine Chemical compound C1CC2C[C@H](N)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 RJNGJYWAIUJHOJ-DSHIFKSRSA-N 0.000 claims 1
- XUMALORDVCFWKV-IBGZPJMESA-N 2-amino-N-[(1S)-1-[8-[2-(1-methylpyrazol-4-yl)ethynyl]-1-oxo-2-phenylisoquinolin-3-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C[C@H](NC(=O)C1=C2N=CC=CN2N=C1N)C1=CC2=CC=CC(C#CC3=CN(C)N=C3)=C2C(=O)N1C1=CC=CC=C1 XUMALORDVCFWKV-IBGZPJMESA-N 0.000 claims 1
- QSPOQCXMGPDIHI-UHFFFAOYSA-N 2-amino-n,n-dipropyl-8-[4-(pyrrolidine-1-carbonyl)phenyl]-3h-1-benzazepine-4-carboxamide Chemical compound C1=C2N=C(N)CC(C(=O)N(CCC)CCC)=CC2=CC=C1C(C=C1)=CC=C1C(=O)N1CCCC1 QSPOQCXMGPDIHI-UHFFFAOYSA-N 0.000 claims 1
- NCWQLHHDGDXIJN-UHFFFAOYSA-N 6-(2-chloro-6-methylpyridin-4-yl)-5-(4-fluorophenyl)-1,2,4-triazin-3-amine Chemical compound ClC1=NC(C)=CC(C=2C(=NC(N)=NN=2)C=2C=CC(F)=CC=2)=C1 NCWQLHHDGDXIJN-UHFFFAOYSA-N 0.000 claims 1
- KURQKNMKCGYWRJ-HNNXBMFYSA-N 7-(5-methylfuran-2-yl)-3-[[6-[[(3s)-oxolan-3-yl]oxymethyl]pyridin-2-yl]methyl]triazolo[4,5-d]pyrimidin-5-amine Chemical compound O1C(C)=CC=C1C1=NC(N)=NC2=C1N=NN2CC1=CC=CC(CO[C@@H]2COCC2)=N1 KURQKNMKCGYWRJ-HNNXBMFYSA-N 0.000 claims 1
- 229940126253 ADU-S100 Drugs 0.000 claims 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims 1
- 206010061424 Anal cancer Diseases 0.000 claims 1
- 208000007860 Anus Neoplasms Diseases 0.000 claims 1
- 239000004475 Arginine Substances 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims 1
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 239000002177 L01XE27 - Ibrutinib Substances 0.000 claims 1
- 102000017578 LAG3 Human genes 0.000 claims 1
- 101150030213 Lag3 gene Proteins 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000032271 Malignant tumor of penis Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- YSUIQYOGTINQIN-CLMXYZJCSA-N NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3CO[P@](S)(=O)O[C@@H]4[C@@H](CO[P@](S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3CO[P@](S)(=O)O[C@@H]4[C@@H](CO[P@](S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-CLMXYZJCSA-N 0.000 claims 1
- 206010061309 Neoplasm progression Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000002471 Penile Neoplasms Diseases 0.000 claims 1
- 206010034299 Penile cancer Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 claims 1
- 206010061934 Salivary gland cancer Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 229930006000 Sucrose Natural products 0.000 claims 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 1
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 206010046431 Urethral cancer Diseases 0.000 claims 1
- 206010046458 Urethral neoplasms Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 206010047741 Vulval cancer Diseases 0.000 claims 1
- 208000004354 Vulvar Neoplasms Diseases 0.000 claims 1
- 201000011165 anus cancer Diseases 0.000 claims 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 1
- 229960003852 atezolizumab Drugs 0.000 claims 1
- 229950002916 avelumab Drugs 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 201000000053 blastoma Diseases 0.000 claims 1
- 230000037396 body weight Effects 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 229950009791 durvalumab Drugs 0.000 claims 1
- 201000008184 embryoma Diseases 0.000 claims 1
- 230000002357 endometrial effect Effects 0.000 claims 1
- 229950006370 epacadostat Drugs 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 1
- 229960001507 ibrutinib Drugs 0.000 claims 1
- XYFPWWZEPKGCCK-GOSISDBHSA-N ibrutinib Chemical compound C1=2C(N)=NC=NC=2N([C@H]2CN(CCC2)C(=O)C=C)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 XYFPWWZEPKGCCK-GOSISDBHSA-N 0.000 claims 1
- YKLIKGKUANLGSB-HNNXBMFYSA-N idelalisib Chemical compound C1([C@@H](NC=2[C]3N=CN=C3N=CN=2)CC)=NC2=CC=CC(F)=C2C(=O)N1C1=CC=CC=C1 YKLIKGKUANLGSB-HNNXBMFYSA-N 0.000 claims 1
- 229960003445 idelalisib Drugs 0.000 claims 1
- 229960002751 imiquimod Drugs 0.000 claims 1
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 238000009169 immunotherapy Methods 0.000 claims 1
- 238000001802 infusion Methods 0.000 claims 1
- 229960005386 ipilimumab Drugs 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000005249 lung adenocarcinoma Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 201000005243 lung squamous cell carcinoma Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- YZOQZEXYFLXNKA-UHFFFAOYSA-N n-[4-(4-amino-2-ethylimidazo[4,5-c]quinolin-1-yl)butyl]methanesulfonamide Chemical compound C1=CC=CC2=C(N(C(CC)=N3)CCCCNS(C)(=O)=O)C3=C(N)N=C21 YZOQZEXYFLXNKA-UHFFFAOYSA-N 0.000 claims 1
- 229960003301 nivolumab Drugs 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- GCWIQUVXWZWCLE-INIZCTEOSA-N pelabresib Chemical compound N([C@@H](CC(N)=O)C=1ON=C(C=1C1=CC=CC=C11)C)=C1C1=CC=C(Cl)C=C1 GCWIQUVXWZWCLE-INIZCTEOSA-N 0.000 claims 1
- 201000002628 peritoneum cancer Diseases 0.000 claims 1
- DTYWJKSSUANMHD-UHFFFAOYSA-N preladenant Chemical compound C1=CC(OCCOC)=CC=C1N1CCN(CCN2C3=C(C4=NC(=NN4C(N)=N3)C=3OC=CC=3)C=N2)CC1 DTYWJKSSUANMHD-UHFFFAOYSA-N 0.000 claims 1
- 229950008939 preladenant Drugs 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 229950010550 resiquimod Drugs 0.000 claims 1
- BXNMTOQRYBFHNZ-UHFFFAOYSA-N resiquimod Chemical compound C1=CC=CC2=C(N(C(COCC)=N3)CC(C)(C)O)C3=C(N)N=C21 BXNMTOQRYBFHNZ-UHFFFAOYSA-N 0.000 claims 1
- 230000004044 response Effects 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 239000005720 sucrose Substances 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 230000005751 tumor progression Effects 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 229940125117 ulevostinag Drugs 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
- 201000005102 vulva cancer Diseases 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024218898A JP2025060696A (ja) | 2018-09-28 | 2024-12-13 | Ｃｄ８イメージングコンストラクト及びその使用方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862738938P | 2018-09-28 | 2018-09-28 | |
| US62/738,938 | 2018-09-28 | ||
| US201962826606P | 2019-03-29 | 2019-03-29 | |
| US62/826,606 | 2019-03-29 | ||
| PCT/US2019/053642 WO2020069433A1 (en) | 2018-09-28 | 2019-09-27 | Cd8 imaging constructs and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024218898A Division JP2025060696A (ja) | 2018-09-28 | 2024-12-13 | Ｃｄ８イメージングコンストラクト及びその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022501402A JP2022501402A (ja) | 2022-01-06 |
| JP2022501402A5 JP2022501402A5 (https=) | 2022-10-05 |
| JPWO2020069433A5 true JPWO2020069433A5 (https=) | 2022-10-05 |
Family
ID=69949940
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021517437A Pending JP2022501402A (ja) | 2018-09-28 | 2019-09-27 | Ｃｄ８イメージングコンストラクト及びその使用方法 |
| JP2024218898A Pending JP2025060696A (ja) | 2018-09-28 | 2024-12-13 | Ｃｄ８イメージングコンストラクト及びその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024218898A Pending JP2025060696A (ja) | 2018-09-28 | 2024-12-13 | Ｃｄ８イメージングコンストラクト及びその使用方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20220001043A1 (https=) |
| EP (2) | EP4205769A1 (https=) |
| JP (2) | JP2022501402A (https=) |
| KR (1) | KR20210087938A (https=) |
| CN (2) | CN113166255A (https=) |
| AU (1) | AU2019351264A1 (https=) |
| CA (1) | CA3113080A1 (https=) |
| WO (1) | WO2020069433A1 (https=) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2904969C (en) | 2013-03-13 | 2025-06-17 | Imaginab, Inc. | DIFFERENTIATION CLUSTER ANTIGEN-BINDING GENETIC CONSTRUCTIONS 8 |
| MX2021012208A (es) | 2013-10-04 | 2023-01-19 | Infinity Pharmaceuticals Inc | Compuestos heterocíclicos y usos de los mismos. |
| NZ724368A (en) | 2014-03-19 | 2023-07-28 | Infinity Pharmaceuticals Inc | Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders |
| WO2017027325A1 (en) | 2015-08-07 | 2017-02-16 | Imaginab, Inc. | Antigen binding constructs to target molecules |
| EP4585268A3 (en) | 2015-09-14 | 2025-10-15 | Twelve Therapeutics, Inc. | Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same |
| WO2019236684A1 (en) | 2018-06-08 | 2019-12-12 | Imaginab, Inc. | Antigen binding constructs to cd4 |
| GB2584086A (en) * | 2019-05-17 | 2020-11-25 | Univ Oxford Innovation Ltd | A method for identity validation and quality assurance of quantitative magnetic resonance imaging protocols |
| CA3195886A1 (en) * | 2020-09-17 | 2022-03-24 | Sunnybay Biotech, Inc | Herv-k antibody therapeutics |
| EP4274901A1 (en) | 2021-01-11 | 2023-11-15 | Sana Biotechnology, Inc. | Use of cd8-targeted viral vectors |
| EP4430167A1 (en) | 2021-11-10 | 2024-09-18 | Iovance Biotherapeutics, Inc. | Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes |
| US20250059560A1 (en) | 2021-12-16 | 2025-02-20 | Sana Biotechnology, Inc. | Methods and systems of particle production |
| WO2023133595A2 (en) | 2022-01-10 | 2023-07-13 | Sana Biotechnology, Inc. | Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses |
| US20250144235A1 (en) | 2022-02-02 | 2025-05-08 | Sana Biotechnology, Inc. | Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses |
| US20250222027A1 (en) | 2022-04-01 | 2025-07-10 | Sana Biotechnology, Inc. | Cytokine receptor agonist and viral vector combination therapies |
| CN115927342B (zh) * | 2022-07-08 | 2025-09-23 | 新疆医科大学 | 特异识别CD8α分子的高亲和力核酸适配体 |
| WO2024026377A1 (en) | 2022-07-27 | 2024-02-01 | Sana Biotechnology, Inc. | Methods of transduction using a viral vector and inhibitors of antiviral restriction factors |
| US20260055146A1 (en) | 2022-08-24 | 2026-02-26 | Sana Biotechnology, Inc. | Delivery of heterologous proteins |
| US20260098062A1 (en) | 2022-09-21 | 2026-04-09 | Sana Biotechnology, Inc. | Lipid particles comprising variant paramyxovirus attachment glycoproteins and uses thereof |
| WO2024119157A1 (en) | 2022-12-02 | 2024-06-06 | Sana Biotechnology, Inc. | Lipid particles with cofusogens and methods of producing and using the same |
| EP4644874A1 (en) | 2022-12-26 | 2025-11-05 | FUJIFILM Corporation | Fluorescence intensity enhancing agent, method for enhancing fluorescence intensity of fluorescently labeled target biological material, and fluorescence detection kit |
| CN116130131B (zh) * | 2022-12-30 | 2026-02-06 | 中国核动力研究设计院 | 一种一回路压力边界泄漏辐射监测装置及其监测方法 |
| JP2026502532A (ja) * | 2023-01-12 | 2026-01-23 | ナショナル ユニバーシティ オブ シンガポール | Ｔ細胞及びｎｋ細胞悪性腫瘍の免疫療法のためのｃｄ８発現及びキメラ抗原受容体の遮断 |
| WO2024220597A2 (en) | 2023-04-18 | 2024-10-24 | Sana Biotechnology, Inc. | Digital droplet based assay for detecting replication competent lentiviral vector |
| KR20260016952A (ko) | 2023-05-23 | 2026-02-04 | 사나 바이오테크놀로지, 인크. | 탠덤 퓨소젠 및 관련 지질 입자 |
| WO2025064435A1 (en) | 2023-09-19 | 2025-03-27 | Imaginab, Inc. | Antigen binding constructs directed to integrin αvβ6 |
| WO2025184529A1 (en) | 2024-03-01 | 2025-09-04 | Sana Biotechnology, Inc. | Viral particles with fusogen display and related compositions and methods |
| US12086990B1 (en) * | 2024-04-23 | 2024-09-10 | MultiFunctional Imaging LLC | Systems and methods for simultaneous imaging of multiple positron emission tomography (PET) tracers |
| US20260056209A1 (en) | 2024-06-14 | 2026-02-26 | Gilead Sciences, Inc. | Anti-ccr8 antibodies and uses thereof |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5342606A (en) | 1984-10-18 | 1994-08-30 | Board Of Regents, The University Of Texas System | Polyazamacrocyclic compounds for complexation of metal ions |
| US5316757A (en) | 1984-10-18 | 1994-05-31 | Board Of Regents, The University Of Texas System | Synthesis of polyazamacrocycles with more than one type of side-chain chelating groups |
| US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5739294A (en) | 1991-12-10 | 1998-04-14 | The Dow Chemical Company | Bicyclopol yazamacrocyclophosphonic acid complexes for use as contrast agents |
| US5428139A (en) | 1991-12-10 | 1995-06-27 | The Dow Chemical Company | Bicyclopolyazamacrocyclophosphonic acid complexes for use as radiopharmaceuticals |
| US5480990A (en) | 1991-12-10 | 1996-01-02 | The Dow Chemical Company | Bicyclopolyazamacrocyclocarboxylic acid complexes for use as contrast agents |
| US5385893A (en) | 1993-05-06 | 1995-01-31 | The Dow Chemical Company | Tricyclopolyazamacrocyclophosphonic acids, complexes and derivatives thereof, for use as contrast agents |
| US5462725A (en) | 1993-05-06 | 1995-10-31 | The Dow Chemical Company | 2-pyridylmethylenepolyazamacrocyclophosphonic acids, complexes and derivatives thereof, for use as contrast agents |
| US5834456A (en) | 1996-02-23 | 1998-11-10 | The Dow Chemical Company | Polyazamacrocyclofluoromonoalkylphosphonic acids, and their complexes, for use as contrast agents |
| US6528624B1 (en) | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
| EP1877399A1 (en) * | 2005-04-26 | 2008-01-16 | Pfizer Limited | Triazole derivatives as vasopressin antagonists |
| US8557257B2 (en) * | 2006-03-24 | 2013-10-15 | Oncovac Inc. | Mycobacterial immunotherapy for cancer treatment |
| JP4877766B2 (ja) | 2006-08-25 | 2012-02-15 | 独立行政法人放射線医学総合研究所 | 陽電子放射断層撮像装置及び放射線検出器 |
| US20130137975A1 (en) * | 2010-02-09 | 2013-05-30 | OSI Pharmaceuticals, LLC | Pet imaging |
| CA2826251A1 (en) | 2011-02-03 | 2012-08-09 | Integrated Diagnostics, Inc. | Psa capture agents, compositions, methods and preparation thereof |
| US8993971B2 (en) | 2011-06-15 | 2015-03-31 | The Board Of Trustees Of The Leland Stanford Junior University | High resolution positron emission tomography |
| AU2012282678B2 (en) | 2011-07-11 | 2016-03-03 | California Institute Of Technology | Akt-specific capture agents, compositions, and methods of using and making |
| US8710180B2 (en) | 2011-08-31 | 2014-04-29 | Indi Molecular, Inc. | VEGF-specific capture agents, compositions, and methods of using and making |
| JP2015508903A (ja) * | 2012-02-28 | 2015-03-23 | コーネル ユニヴァーシティー | 前立腺癌におけるアンドロゲン活性のバイオマーカーとしてのｐｓｍａ |
| US20150191543A1 (en) * | 2012-08-06 | 2015-07-09 | The Regents Of The University Of California | Engineered antibody fragments for targeting and imaging cd8 expression in vivo |
| WO2014074907A1 (en) | 2012-11-09 | 2014-05-15 | Indi Molecular, Inc. | C-met-specific capture agents, compositions, and methods of using and making |
| CA2904969C (en) | 2013-03-13 | 2025-06-17 | Imaginab, Inc. | DIFFERENTIATION CLUSTER ANTIGEN-BINDING GENETIC CONSTRUCTIONS 8 |
| CN105979872A (zh) | 2013-09-25 | 2016-09-28 | 理查德·R·布莱克 | 正电子发射断层摄影数据的病人特异性分析 |
| DE102014200303B4 (de) | 2014-01-10 | 2015-10-29 | Siemens Aktiengesellschaft | Verfahren zur Durchführung einer Positronenemissionstomographie in einer Hybridanlage und entsprechende Hybridanlage |
| US10844122B2 (en) * | 2015-05-06 | 2020-11-24 | Janssen Biotech, Inc. | Prostate specific membrane antigen (PSMA) bispecific binding agents and uses thereof |
| CN105395209B (zh) | 2015-12-01 | 2018-10-02 | 沈阳东软医疗系统有限公司 | 一种正电子发射断层扫描成像系统及方法 |
| CN115109120A (zh) | 2016-04-04 | 2022-09-27 | 英蒂分子公司 | Cd8-特异性捕获剂、组合物及使用和制备方法 |
| WO2017214766A1 (zh) | 2016-06-12 | 2017-12-21 | 上海联影医疗科技有限公司 | 正电子发射断层成像系统及其图像重建方法 |
| CN111295394B (zh) * | 2017-08-11 | 2024-06-11 | 豪夫迈·罗氏有限公司 | 抗cd8抗体及其用途 |
-
2019
- 2019-09-27 KR KR1020217012365A patent/KR20210087938A/ko active Pending
- 2019-09-27 CN CN201980079379.0A patent/CN113166255A/zh active Pending
- 2019-09-27 US US17/280,137 patent/US20220001043A1/en active Pending
- 2019-09-27 AU AU2019351264A patent/AU2019351264A1/en active Pending
- 2019-09-27 EP EP22182384.2A patent/EP4205769A1/en active Pending
- 2019-09-27 CN CN202211648348.2A patent/CN116271117A/zh active Pending
- 2019-09-27 WO PCT/US2019/053642 patent/WO2020069433A1/en not_active Ceased
- 2019-09-27 JP JP2021517437A patent/JP2022501402A/ja active Pending
- 2019-09-27 EP EP19866804.8A patent/EP3856786A4/en active Pending
- 2019-09-27 CA CA3113080A patent/CA3113080A1/en active Pending
-
2024
- 2024-12-13 JP JP2024218898A patent/JP2025060696A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2020069433A5 (https=) | ||
| JP2022501402A5 (https=) | ||
| Christensen et al. | Quantitative PET imaging of PD-L1 expression in xenograft and syngeneic tumour models using a site-specifically labelled PD-L1 antibody | |
| Rainer et al. | The prognostic value of [123I]-vascular endothelial growth factor ([123I]-VEGF) in glioma | |
| Jadvar et al. | Evaluation of recurrent gastric malignancy with [F-18]-FDG positron emission tomography | |
| Lindenberg et al. | Safety and biodistribution of 111In-amatuximab in patients with mesothelin expressing cancers using single photon emission computed tomography-computed tomography (SPECT-CT) imaging | |
| Muros et al. | Utility of fluorine-18-fluorodeoxyglucose positron emission tomography in differentiated thyroid carcinoma with negative radioiodine scans and elevated serum thyroglobulin levels | |
| US20090297439A1 (en) | Anti-met monoclonal antibody, fragments and derivatives thereof for use in tumor diagnosis, corresponding compositions and kits | |
| Kristensen et al. | Monitoring CD8a+ T cell responses to radiotherapy and CTLA-4 blockade using [64Cu] NOTA-CD8a PET imaging | |
| Wei et al. | HER2-targeted multimodal imaging of anaplastic thyroid cancer | |
| Shih et al. | 111In-cetuximab as a diagnostic agent by accessible epidermal growth factor (EGF) receptor targeting in human metastatic colorectal carcinoma | |
| Foubert et al. | Sensitivity of pretargeted immunoPET using 68Ga-peptide to detect colonic carcinoma liver metastases in a murine xenograft model: comparison with 18FDG PET-CT | |
| Liu et al. | [64Cu] Cu-FAP-NOX, a N-oxalyl modified cyclic peptide for FAP PET imaging with a flexible imaging time window | |
| Von Schulthess et al. | Imaging and PET—PET/CTimaging | |
| Raderer et al. | 123I-labelled vasoactive intestinal peptide receptor scintigraphy in patients with colorectal cancer | |
| Vahidfar et al. | Recent Advances of Copper-64 Based Radiopharmaceuticals in | |
| Raderer et al. | Comparison of iodine-123-vasoactive intestinal peptide receptor scintigraphy and indium-111-CYT-103 immunoscintigraphy | |
| EP2127683A1 (en) | Anti-Met monoclonal antibody, fragments and derivatives thereof for use in tumor imaging, corresponding compositions and kits | |
| Volkan-Salancı et al. | Nuclear medicine in thyroid diseases in pediatric and adolescent patients | |
| Draisma et al. | Gallium-67 as a Tumor-seeking Agent in Lymphomas-a Review | |
| Seivert et al. | Endoscopic findings in case of incidental colonic uptake in PET-CT how to improve PET-CT specificity? | |
| Kameswaran et al. | Preclinical evaluation of 131I-Bevacizumab–A prospective agent for radioimmunotherapy in VEGF expressing cancers | |
| El-Khodary et al. | The role of PET/CT in the management of head and neck squamous cell carcinoma | |
| RU2785387C1 (ru) | Способ оценки неоадъювантной химиотерапии у больных раком молочной железы с гиперэкспрессией her2/neu | |
| Tully | Radioimmunotherapy and ImmunoPET Imaging Targeting Delta-like Ligand 3 in Small Cell Lung Cancer |